請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/9783
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林中天 | |
dc.contributor.author | Pei-Yun Huang | en |
dc.contributor.author | 黃珮筠 | zh_TW |
dc.date.accessioned | 2021-05-20T20:41:06Z | - |
dc.date.available | 2013-07-30 | |
dc.date.available | 2021-05-20T20:41:06Z | - |
dc.date.copyright | 2008-07-30 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-07-22 | |
dc.identifier.citation | Akdemir G, Ergungor MF, Sezer M, Albayrak L, Daglioglu E & Kilinc K. (2005). Therapeutic efficacy of intraventricular cyclosporine A and methylprednisolone on a global cerebral ischemia model in rats. Neurol Res 27, 827-834.
Arvin KL, Han BH, Du Y, Lin SZ, Paul SM & Holtzman DM. (2002). Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Ann Neurol 52, 54-61. Ashley RA. (1999). Clinical trials of a matrix metalloproteinase inhibitor in human periodontal disease. SDD Clinical Research Team. Ann N Y Acad Sci 878, 335-346. Askar I & Bozkurt M. (2002). Protective effects of immunosuppressants and steroids against ischemia-reperfusion injury in cremaster muscle flap at microcirculatory level. Microsurgery 22, 361-366. Baptiste DC & Fehlings MG. (2006). Pharmacological approaches to repair the injured spinal cord. J Neurotrauma 23, 318-334. Baptiste DC, Hartwick AT, Jollimore CA, Baldridge WH, Seigel GM & Kelly ME. (2004). An investigation of the neuroprotective effects of tetracycline derivatives in experimental models of retinal cell death. Mol Pharmacol 66, 1113-1122. Bernstein SL, Guo Y, Kelman SE, Flower RW & Johnson MA. (2003). Functional and cellular responses in a novel rodent model of anterior ischemic optic neuropathy. Invest Ophthalmol Vis Sci 44, 4153-4162. Bonne C, Muller A & Villain M. (1998). Free radicals in retinal ischemia. Gen Pharmacol 30, 275-280. Brundula V, Rewcastle NB, Metz LM, Bernard CC & Yong VW. (2002). Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 125, 1297-1308. Buchi ER. (1992). Cell death in the rat retina after a pressure-induced ischaemia-reperfusion insult: an electron microscopic study. I. Ganglion cell layer and inner nuclear layer. Exp Eye Res 55, 605-613. Buchi ER, Suivaizdis I & Fu J. (1991). Pressure-induced retinal ischemia in rats: an experimental model for quantitative study. Ophthalmologica 203, 138-147. Chao HM & Osborne NN. (2001). Topically applied clonidine protects the rat retina from ischaemia/reperfusion by stimulating alpha(2)-adrenoceptors and not by an action on imidazoline receptors. Brain Res 904, 126-136. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH & Friedlander RM. (2000). Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6, 797-801. Chidlow G, Schmidt KG, Wood JP, Melena J & Osborne NN. (2002). Alpha-lipoic acid protects the retina against ischemia-reperfusion. Neuropharmacology 43, 1015-1025. Chimalakonda AP & Mehvar R. (2004). Effects of duration of ischemia and donor pretreatment with methylprednisolone or its macromolecular prodrug on the disposition of indocyanine green in cold-preserved rat livers. Pharm Res 21, 1000-1008. Danton GH & Dietrich WD. (2003). Inflammatory mechanisms after ischemia and stroke. J Neuropathol Exp Neurol 62, 127-136. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DL, Luecke S, Phebus LA, Bymaster FP & Paul SM. (2001). Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A 98, 14669-14674. Egeblad M & Werb Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2, 161-174. Elewa HF, Hilali H, Hess DC, Machado LS & Fagan SC. (2006). Minocycline for short-term neuroprotection. Pharmacotherapy 26, 515-521. Fan LW, Lin S, Pang Y, Rhodes PG & Cai Z. (2006). Minocycline attenuates hypoxia-ischemia-induced neurological dysfunction and brain injury in the juvenile rat. Eur J Neurosci 24, 341-350. Foulds WS & Johnson NF. (1974). Rabbit electroretinogram during recovery from induced ischaemia. Trans Ophthalmol Soc U K 94, 383-393. Fox C, Dingman A, Derugin N, Wendland MF, Manabat C, Ji S, Ferriero DM & Vexler ZS. (2005). Minocycline confers early but transient protection in the immature brain following focal cerebral ischemia-reperfusion. J Cereb Blood Flow Metab 25, 1138-1149. Glanemann M, Strenziok R, Kuntze R, Munchow S, Dikopoulos N, Lippek F, Langrehr JM, Dietel M, Neuhaus P & Nussler AK. (2004). Ischemic preconditioning and methylprednisolone both equally reduce hepatic ischemia/reperfusion injury. Surgery 135, 203-214. Goldblum D & Mittag T. (2002). Prospects for relevant glaucoma models with retinal ganglion cell damage in the rodent eye. Vision Res 42, 471-478. Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA & Rifkin BR. (1991). Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 2, 297-321. Granit R. (1933). The components of the retinal action potential in mammals and their relation to the discharge in the optic nerve. J Physiol 77, 207-239. Greenwald RA, Moak SA, Ramamurthy NS & Golub LM. (1992). Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate bone damage. J Rheumatol 19, 927-938. Grozdanic SD, Sakaguchi DS, Kwon YH, Kardon RH & Sonea IM. (2003). Functional characterization of retina and optic nerve after acute ocular ischemia in rats. Invest Ophthalmol Vis Sci 44, 2597-2605. Guo L, Moss SE, Alexander RA, Ali RR, Fitzke FW & Cordeiro MF. (2005). Retinal ganglion cell apoptosis in glaucoma is related to intraocular pressure and IOP-induced effects on extracellular matrix. Invest Ophthalmol Vis Sci 46, 175-182. Gustavsson C, Agardh CD, Hagert P & Agardh E. (2008). Inflammatory markers in nondiabetic and diabetic rat retinas exposed to ischemia followed by reperfusion. Retina 28, 645-652. Hayreh SS & Weingeist TA. (1980). Experimental occlusion of the central artery of the retina. IV: Retinal tolerance time to acute ischaemia. Br J Ophthalmol 64, 818-825. Hewlett KA & Corbett D. (2006). Delayed minocycline treatment reduces long-term functional deficits and histological injury in a rodent model of focal ischemia. Neuroscience 141, 27-33. Hirooka K, Miyamoto O, Jinming P, Du Y, Itano T, Baba T, Tokuda M & Shiraga F. (2006). Neuroprotective effects of D-allose against retinal ischemia-reperfusion injury. Invest Ophthalmol Vis Sci 47, 1653-1657. Hughes WF. (1991). Quantitation of ischemic damage in the rat retina. Exp Eye Res 53, 573-582. Jehle T, Wingert K, Dimitriu C, Meschede W, Lasseck J, Bach M & Lagreze WA. (2008). Quantification of ischemic damage in the rat retina: a comparative study using evoked potentials, electroretinography, and histology. Invest Ophthalmol Vis Sci 49, 1056-1064. Jian Liu K & Rosenberg GA. (2005). Matrix metalloproteinases and free radicals in cerebral ischemia. Free Radic Biol Med 39, 71-80. Johnson MA & McPhee TJ. (1993). Electroretinographic findings in iris neovascularization due to acute central retinal vein occlusion. Arch Ophthalmol 111, 806-814. Levkovitch-Verbin H, Kalev-Landoy M, Habot-Wilner Z & Melamed S. (2006). Minocycline delays death of retinal ganglion cells in experimental glaucoma and after optic nerve transection. Arch Ophthalmol 124, 520-526. Lin S, Zhang Y, Dodel R, Farlow MR, Paul SM & Du Y. (2001). Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons. Neurosci Lett 315, 61-64. Lipton P. (1999). Ischemic cell death in brain neurons. Physiol Rev 79, 1431-1568. Maier K, Merkler D, Gerber J, Taheri N, Kuhnert AV, Williams SK, Neusch C, Bahr M & Diem R. (2007). Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation. Neurobiol Dis 25, 514-525. Mali RS, Cheng M & Chintala SK. (2005). Intravitreous injection of a membrane depolarization agent causes retinal degeneration via matrix metalloproteinase-9. Invest Ophthalmol Vis Sci 46, 2125-2132. Manabe S, Gu Z & Lipton SA. (2005). Activation of matrix metalloproteinase-9 via neuronal nitric oxide synthase contributes to NMDA-induced retinal ganglion cell death. Invest Ophthalmol Vis Sci 46, 4747-4753. Mathalone N, Lahat N, Rahat MA, Bahar-Shany K, Oron Y & Geyer O. (2007). The involvement of matrix metalloproteinases 2 and 9 in rat retinal ischemia. Graefes Arch Clin Exp Ophthalmol 245, 725-732. Mukaida Y, Machida S, Masuda T & Tazawa Y. (2004). Correlation of retinal function with retinal histopathology following ischemia-reperfusion in rat eyes. Curr Eye Res 28, 381-389. Muratore A, Ribero D, Ferrero A, Bergero R & Capussotti L. (2003). Prospective randomized study of steroids in the prevention of ischaemic injury during hepatic resection with pedicle clamping. Br J Surg 90, 17-22. Narfstrom K. (2002). Workshop in veterinary electroretinography. In Amenrican College of Veterinary Ophthalmologists, pp. 1-8. Denver, Colorado, USA. Neufeld AH, Kawai S, Das S, Vora S, Gachie E, Connor JR & Manning PT. (2002). Loss of retinal ganglion cells following retinal ischemia: the role of inducible nitric oxide synthase. Exp Eye Res 75, 521-528. Nickells RW. (1999). Apoptosis of retinal ganglion cells in glaucoma: an update of the molecular pathways involved in cell death. Surv Ophthalmol 43 Suppl 1, S151-161. Nickells RW & Zack DJ. (1996). Apoptosis in ocular disease: a molecular overview. Ophthalmic Genet 17, 145-165. Osborne NN, Casson RJ, Wood JP, Chidlow G, Graham M & Melena J. (2004a). Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog Retin Eye Res 23, 91-147. Osborne NN, Cazevieille C, Carvalho AL, Larsen AK & DeSantis L. (1997). In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent. Brain Res 751, 113-123. Osborne NN, Melena J, Chidlow G & Wood JP. (2001). A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma. Br J Ophthalmol 85, 1252-1259. Osborne NN, Ugarte M, Chao M, Chidlow G, Bae JH, Wood JP & Nash MS. (1999). Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv Ophthalmol 43 Suppl 1, S102-128. Osborne NN, Wood JP, Chidlow G, Casson R, DeSantis L & Schmidt KG. (2004b). Effectiveness of levobetaxolol and timolol at blunting retinal ischaemia is related to their calcium and sodium blocking activities: relevance to glaucoma. Brain Res Bull 62, 525-528. Pearl JM, Nelson DP, Schwartz SM, Wagner CJ, Bauer SM, Setser EA & Duffy JY. (2002). Glucocorticoids reduce ischemia-reperfusion-induced myocardial apoptosis in immature hearts. Ann Thorac Surg 74, 830-836; discussion 836-837. Pellegrini-Giampietro DE, Cherici G, Alesiani M, Carla V & Moroni F. (1990). Excitatory amino acid release and free radical formation may cooperate in the genesis of ischemia-induced neuronal damage. J Neurosci 10, 1035-1041. Power C, Henry S, Del Bigio MR, Larsen PH, Corbett D, Imai Y, Yong VW & Peeling J. (2003). Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Ann Neurol 53, 731-742. Pulitano C & Aldrighetti L. (2008). The protective role of steroids in ischemia-reperfusion injury of the liver. Curr Pharm Des 14, 496-503. Rhee DJ, Ramos-Esteban JC & Nipper KS. (2006). Rapid resolution of topiramate-induced angle-closure glaucoma with methylprednisolone and mannitol. Am J Ophthalmol 141, 1133-1134. Riazi-Esfahani M, Kiumehr S, Asadi-Amoli F, Lashay AR & Dehpour AR. (2008). Morphine pretreatment provides histologic protection against ischemia-reperfusion injury in rabbit retina. Retina 28, 511-517. Rifkin BR, Vernillo AT & Golub LM. (1993). Blocking periodontal disease progression by inhibiting tissue-destructive enzymes: a potential therapeutic role for tetracyclines and their chemically-modified analogs. J Periodontol 64, 819-827. Safa R & Osborne NN. (2000). Retinas from albino rats are more susceptible to ischaemic damage than age-matched pigmented animals. Brain Res 862, 36-42. Saidi RF, Chang J, Verb S, Brooks S, Nalbantoglu I, Adsay V & Jacobs MJ. (2007). The effect of methylprednisolone on warm ischemia-reperfusion injury in the liver. Am J Surg 193, 345-347; discussion 347-348. Saito S, Ohashi M, Naito A, Fukaya Y, Suzuki Y & Araie M. (2005). Neuroprotective effect of the novel Na+/Ca2+ channel blocker NS-7 on rat retinal ganglion cells. Jpn J Ophthalmol 49, 371-376. Sanchez Mejia RO, Ona VO, Li M & Friedlander RM. (2001). Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery 48, 1393-1399; discussion 1399-1401. Schmidt M, Giessl A, Laufs T, Hankeln T, Wolfrum U & Burmester T. (2003). How does the eye breathe? Evidence for neuroglobin-mediated oxygen supply in the mammalian retina. J Biol Chem 278, 1932-1935. Selles-Navarro I, Villegas-Perez MP, Salvador-Silva M, Ruiz-Gomez JM & Vidal-Sanz M. (1996). Retinal ganglion cell death after different transient periods of pressure-induced ischemia and survival intervals. A quantitative in vivo study. Invest Ophthalmol Vis Sci 37, 2002-2014. Shibuki H, Katai N, Kuroiwa S, Kurokawa T, Arai J, Matsumoto K, Nakamura T & Yoshimura N. (2002). Expression and neuroprotective effect of hepatocyte growth factor in retinal ischemia-reperfusion injury. Invest Ophthalmol Vis Sci 43, 528-536. Shimazawa M, Yamashima T, Agarwal N & Hara H. (2005). Neuroprotective effects of minocycline against in vitro and in vivo retinal ganglion cell damage. Brain Res 1053, 185-194. Sivak JM & Fini ME. (2002). MMPs in the eye: emerging roles for matrix metalloproteinases in ocular physiology. Prog Retin Eye Res 21, 1-14. Slivka AP & Murphy EJ. (2001). High-dose methylprednisolone treatment in experimental focal cerebral ischemia. Exp Neurol 167, 166-172. Smith DL, Woodman B, Mahal A, Sathasivam K, Ghazi-Noori S, Lowden PA, Bates GP & Hockly E. (2003). Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann Neurol 54, 186-196. Smith GG & Baird CD. (1952). Survival time of retinal cells when deprived of their blood supply by increased intraocular pressure. Am J Ophthalmol 35, 133-136. Stone J, Maslim J, Valter-Kocsi K, Mervin K, Bowers F, Chu Y, Barnett N, Provis J, Lewis G, Fisher SK, Bisti S, Gargini C, Cervetto L, Merin S & Peer J. (1999). Mechanisms of photoreceptor death and survival in mammalian retina. Prog Retin Eye Res 18, 689-735. Tikka T, Fiebich BL, Goldsteins G, Keinanen R & Koistinaho J. (2001). Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 21, 2580-2588. Tikka TM & Koistinaho JE. (2001). Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol 166, 7527-7533. Uckermann O, Uhlmann S, Pannicke T, Francke M, Gamsalijew R, Makarov F, Ulbricht E, Wiedemann P, Reichenbach A, Osborne NN & Bringmann A. (2005). Ischemia-reperfusion causes exudative detachment of the rabbit retina. Invest Ophthalmol Vis Sci 46, 2592-2600. Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E, Ferrante RJ, Kristal BS & Friedlander RM. (2003). Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci U S A 100, 10483-10487. Wells JE, Hurlbert RJ, Fehlings MG & Yong VW. (2003). Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain 126, 1628-1637. Wood JP, Schmidt KG, Melena J, Chidlow G, Allmeier H & Osborne NN. (2003). The beta-adrenoceptor antagonists metipranolol and timolol are retinal neuroprotectants: comparison with betaxolol. Exp Eye Res 76, 505-516. Xu L, Fagan SC, Waller JL, Edwards D, Borlongan CV, Zheng J, Hill WD, Feuerstein G & Hess DC. (2004). Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC Neurol 4, 7. Yong VW, Power C, Forsyth P & Edwards DR. (2001). Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2, 502-511. Yoo MH, Lee JY, Lee SE, Koh JY & Yoon YH. (2004). Protection by pyruvate of rat retinal cells against zinc toxicity in vitro, and pressure-induced ischemia in vivo. Invest Ophthalmol Vis Sci 45, 1523-1530. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T & Koistinaho J. (1998). Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A 95, 15769-15774. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH & Koistinaho J. (1999). A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci U S A 96, 13496-13500. Zeevalk GD & Nicklas WJ. (1992). Evidence that the loss of the voltage-dependent Mg2+ block at the N-methyl-D-aspartate receptor underlies receptor activation during inhibition of neuronal metabolism. J Neurochem 59, 1211-1220. Zemke D & Majid A. (2004). The potential of minocycline for neuroprotection in human neurologic disease. Clin Neuropharmacol 27, 293-298. Zhang C, Lei B, Lam TT, Yang F, Sinha D & Tso MO. (2004). Neuroprotection of photoreceptors by minocycline in light-induced retinal degeneration. Invest Ophthalmol Vis Sci 45, 2753-2759. Zhang X, Sakamoto T, Hata Y, Kubota T, Hisatomi T, Murata T, Ishibashi T & Inomata H. (2002). Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats. Exp Eye Res 74, 577-584. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu DC, Gullans S, Ferrante RJ, Przedborski S, Kristal BS & Friedlander RM. (2002). Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417, 74-78. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/9783 | - |
dc.description.abstract | 美諾四環黴素(minocycline)是一種半合成、四環素(tetracycline)的第二代衍生物,應用於治療格蘭氏陰性菌或陽性菌的感染,近年來在許多研究腦部缺血或退化性疾病的實驗模式中,被發現具有神經保護的效果。
本篇研究目標在探討腹腔注射藥物minocycline是否對於視網膜缺血性病變有神經保護效果。本實驗採高眼內壓誘發視網膜缺血模式,大鼠眼前房以30號針頭穿刺,並連接上含生理食鹽水的點滴袋,將眼內壓提高到130mmHg,造成眼底視網膜完全缺血的狀態持續45分鐘。治療組分為兩個劑量,分別為每日45 mg/kg及90 mg/kg的minocycline腹腔注射。傷害評估利用缺血後第三天及第七天的視網膜電波圖,來檢查視網膜功能的改變,以及缺血後七天在組織病理形態及視網膜的厚度改變。其結果並和給予生理食鹽水和methylprednisolone的組別作比較分析。 視網膜電波圖的結果顯示,在給予缺血再灌流的傷害後,缺血眼的b波有顯著下降的趨勢(平均b波波幅損失74±2%),而相對的a波影響較少。給予兩種劑量45 mg/kg及90 mg/kg的minocycline都有改善視網膜功能受損的情形,其視網膜電波圖的結果,分別為損失37±6%及43±2%的b波。組織病理結果顯示內層視網膜傷害均比外層強,而內叢狀層與外核層的比值(IPL/ONL ratio) 與正常的百分比分析(% of正常),缺血無治療組(IR-control)只剩下44.1%,45 mg/kg及90 mg/kg的minocycline治療組(Mino-45、Mino-90)顯示存留程度為93.4%和94.1%,而methylprednisolone治療組(MP)剩存的百分比可高達96.7%,幾乎沒有下降。根據結果指出,minocycline與methylprednisolone對於大鼠視網膜缺血再灌流模式,在組織病理的型態劑量上展現出良好的視網膜視網膜保護效果,而在視網膜功能方面可提供中等程度的神經保護效果。 | zh_TW |
dc.description.abstract | Minocycline, a microglial inhibitor, has recently been shown to be neuroprotective in various models of cerebral ischemia and degenerative diseases. The purpose of this study was to investigate the neuroprotective effect of intraperitoneal minocycline against the retinal ischemia-reperfusion (IR) injury in the rat. The retinal IR injury model was induced in Sprague-Dawley rats by infusing normal saline (0.9%) into anterior chamber of eye to creat a higher intraocular pressure (IOP) than blood pressure for 45 min. Minocycline was given intraperitoneally at dosages of 45 mg/kg per day and 90 mg/kg per day in rats of IR injury model. The effects were evaluated by electroretinogram (ERG) 3 days and 7 days after ischemia respectively, and compared with the groups treated with saline and methyprenisolone (30mg/kg, IV). Present results have indicated that ischemia-reperfusion (IR) injury caused retinal damage characterized by a decline in electroretinogram b-wave (loss of 74±2% b-wave, n=5) whereas the a-wave was relatively unaffected. Administration of minocycline in both doses ameliorated the damage of retinal function. The b-wave of ERG dropped down 37±6% in the 90 mg/kg/day group ( n=6) and 43±2% in the 45mg/kg/day group (n=6). In the morphometrical histology, the retinal inner plexiform layer/outer nuclear layer (IPL/ONL) ratio was reduced following IR damage compared with that in the normal control. The IPL/ONL ratio was reduced to 44.1% in the IR-control group, 93.4% and 94.1% in the Mino-45 and Mino-90 group. While the IPL/ONL ratio was preserved to 96.7% in the MP group. According to the results, minocycline and methylprednisolone showed significantly good neuroprotective effects demonstrated in histology, but moderate neuroprotective effects in retinal function of the rats under retinal ischemia-reperfusion injury. | en |
dc.description.provenance | Made available in DSpace on 2021-05-20T20:41:06Z (GMT). No. of bitstreams: 1 ntu-97-R94629032-1.pdf: 789970 bytes, checksum: 4c0b8dfc7f839a5b0af7d477740ea9f8 (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | 中文摘要............................................................1.
英文摘要............................................................2. 第一章 緒言........................................................4. 第一節 視網膜缺血性病變..........................................4. 第二節 視網膜神經保護概念與治療策略..............................4. 一、 視網膜缺血再灌流導致的傷害機轉............................4. 二、 神經保護策略及途徑........................................8. 第三節 視網膜缺血再灌流性病變之動物模式.........................10. 一、 簡介.....................................................10. 二、 視網膜缺血性病變評估.....................................11. 第四節 Minocycline的簡介與應用..................................14. 第五節 Methylprednisolone的治療策略..............................18. 第六節 研究目的.................................................19. 第二章 實驗材料與方法.............................................20. 第一節 實驗動物.................................................20. 第二節 實驗材料與分組...........................................20. 第三節 大鼠視網膜缺血再灌流模式.................................21. 第四節 藥物的劑量與投予.........................................21. 第五節 視網膜電波圖的紀錄與分析.................................22. 第六節 組織病理學切片評估.......................................23. 第七節 統計與分析方法...........................................24. 第三章 實驗結果...................................................25. 第一節 視網膜電波圖電生理分析結果...............................25. 一、 建立高眼內壓導致視網膜缺血再灌流模式.....................25. 二、 視網膜電波圖b-wave ratio下降幅度分析比較..................31. 三、 視網膜電波圖a波和b波綜合比較...........................39. 第二節 組織病理型態分析報告.....................................41. 一、 各層視網膜厚度病變比較...................................41. 二、 內叢狀層與外核層的比值分析...............................47. 第四章 討論.......................................................49. 第一節 視網膜缺血性病變的模式...................................49. 第二節 神經保護藥物的選擇.......................................50. 第三節 視網膜電波圖討論.........................................51. 一、 視網膜功能評估的選擇.....................................51. 二、 統計視網膜保護效力結果與文獻之討論.......................52. 三、 不同光源強度的使用與討論.................................56. 第四節 組織病理型態的討論.......................................59. 一、 缺血再灌流對病理型態上之影響.............................59. 二、 病理結果的統計與文獻之討論...............................60. 第五節 評估藥物保護效果.........................................62. 第五章 結論.......................................................64. 第六章 參考文獻...................................................65. | |
dc.language.iso | zh-TW | |
dc.title | Minocycline對於大鼠視網膜缺血再灌流性傷害的神經保護效力 | zh_TW |
dc.title | The Neuroprotective Effects of Minocyline on Retinal Ischemia-Reperfusion Injury in the rat | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 葉力森,劉振軒 | |
dc.subject.keyword | 視網膜缺血,神經保護,視網膜電波圖,美諾四環黴素,再灌流性傷害, | zh_TW |
dc.subject.keyword | retinal ischemia-reperfusion injury,ischemia-reperfusion injury,minocycline,electroretinogram,neuroprotective effect, | en |
dc.relation.page | 70 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2008-07-24 | |
dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
dc.contributor.author-dept | 獸醫學研究所 | zh_TW |
顯示於系所單位: | 獸醫學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf | 771.46 kB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。